2021-05-13T13:32:19-05:00 2020-06-30 KPMG LLP 150 W JEFFERSON SUITE 900 DETROIT MI 48226 990 2019-07-01 954335088 Lymphoma Research Foundation % CAROL FLORES LYMP 2123492910 WALL ST PLAZA 88 PINE STREET Suite New York NY 10005 MEGHAN GUTIERREZ CEO 2123492910 2021-05-07 true Nicole Fitzmaurice P01491005 3132303340 2021-05-04 2019 2022-09-23 18:48:47Z MEGHAN GUTIERREZ WALL ST PLAZA 88 PINE STE 240 New York NY 10005 14561407 false X www.lymphoma.org X 2001 NY THE LYMPHOMA RESEARCH FOUNDATION'S MISSION IS TO ERADICATE LYMPHOMA AND SERVE THOSE TOUCHED BY THIS DISEASE. FOR MORE INFORMATION, SEE SCHEDULE O. 21 21 41 10000 0 0 7623538 9778478 3761384 3922980 226544 313409 -61895 -69915 11549571 13944952 1812125 1069898 0 0 2869837 3204493 0 0 1765657 4580164 3897002 9262126 8171393 2287445 5773559 16453671 22709643 3784012 3997100 12669659 18712543 X THE LYMPHOMA RESEARCH FOUNDATION'S (LRF) MISSION IS TO ERADICATE LYMPHOMA AND SERVE THOSE TOUCHED BY THIS DISEASE. SEE SCHEDULE O. false false 2636064 42600 EDUCATIONAL PROGRAMS AND PATIENT SERVICES: LRF PROVIDES A COMPREHENSIVE SERIES OF PROGRAMS AND SERVICES FOR THE LYMPHOMA COMMUNITY INCLUDING, BUT NOT LIMITED TO, CONTINUING MEDICAL EDUCATION, CLINICAL TRIALS INFORMATION SERVICES, DISEASE SPECIFIC PUBLICATIONS AND WEBSITES, IN-PERSON PATIENT WORKSHOPS AND EDUCATIONAL FORUMS, LYMPHOMA HELPLINE, ONLINE SERVICES, PATIENT AID GRANTS, TELECONFERENCES AND WEBCASTS/PODCASTS, WITH A VOLUNTEER COMMUNITY NETWORK. 1931755 1027298 RESEARCH: THE FOUNDATION IS COMMITTED TO FUNDING THE MOST PROMISING LYMPHOMA RESEARCHERS WHO HAVE THE GREATEST POTENTIAL TO ADVANCE PATIENT CARE AND IMPROVE PATIENT OUTCOMES. THROUGH ITS LYMPHOMA CONSORTIA, RESEARCH INITIATIVES, AND SCIENTIFIC WORKSHOPS, LRF MOBILIZES THE RESEARCH COMMUNITY TO SPEED THE DEVELOPMENT AND USE OF NEW TREATMENTS. SEE SCHEDULE O. 799614 COMMUNICATION AND ADVOCACY: THROUGH STRATEGIC COMMUNICATIONS, LRF SEEKS TO RAISE AWARENESS OF LYMPHOMA AND THE NEEDS OF PEOPLE WITH LYMPHOMA. DIGITAL PROGRAMMING ENSURES ACCESS TO ACURATE INFORMATION AND DIGITAL PROGRAMS INCLUDING MOBILE APPS. LRFS ADVOCACY PROGRAM ENABLES VOLUNTEERS TO REPRESENT THE NEEDS OF PEOPLE WITH LYMPHOMA BY SUPPORTING PUBLIC POLICIES WHICH SEEK TO INCREASE FEDERAL FUNDING FOR LYMPHOMA RESEARCH AND ENSURE ACCESS TO HIGH QUALITY CANCER CARE. 5367433 true true false true false false false false false false true false false false false true true false false false false true false false true false false true true true false false false false false false false false true false false false false true true true false false true 44 0 true 41 true false false false false false true true false false false false false false X 21 21 true false false false false false false true true false true true true true true true true true true false true true AL AR CA FL GA HI IL KS KY MD MA MI MN MS MO NV NH NJ NM NY NC OR PA RI SC TN UT VA WV WI X X CAROL FLORES 2123492910 WALL ST PLAZA 88 PINE STE 2400 NEW YORK NY 10005 MEGHAN GUTIERREZ CHIEF EXECUTIVE OFFICER 35.0 0.0 X 288756 0 12739 CAROLINA FLORES SENIOR DIRECTOR OF FINANCE 35.0 0.0 X 141923 0 48229 PEGGY ANN TORNEY CHIEF STRATEGY,COM.&ENGA. OFF. 35.0 0.0 X 109792 0 11242 Kinya Harte DIRECTOR OF COMM. & MARKETING 35.0 0.0 X 92593 0 18693 MICHAEL AKINYELE BOARD MEMBER 1.0 0.0 X 0 0 0 JOSEPH R BERTINO MD BOARD MEMBER (END 6/2020) 1.0 0.0 X 0 0 0 JEFF BLOCK BOARD MEMBER (BEGIN 11/2019) 1.0 0.0 X 0 0 0 ERIC COHEN BOARD MEMBER 1.0 0.0 X 0 0 0 DR MORTON COLEMAN BOARD MEMBER - CHAIR MAB 1.0 0.0 X 0 0 0 TOM CONDON BOARD MEMBER 1.0 0.0 X 0 0 0 STEVEN Eichberg BOARD MEMBER (BEGIN 11/2019) 1.0 0.0 X 0 0 0 KEVIN FENNESSEY VICE CHAIR 1.0 0.0 X 0 0 0 MICHAEL FROY BOARD MEMBER 1.0 0.0 X 0 0 0 THOMAS E GOLDSTONE BOARD MEMBER 1.0 0.0 X 0 0 0 KEITH HOOGLAND BOARD MEMBER 1.0 0.0 X 0 0 0 JOHN LEONARD MD BOARD MEMBER 1.0 0.0 X 0 0 0 ROBERT MCAULEY BOARD MEMBER 1.0 0.0 X 0 0 0 KIM METCALF BOARD MEMBER 1.0 0.0 X 0 0 0 JOHN A NELSON BOARD MEMBER 1.0 0.0 X 0 0 0 LEIGH OLSON SECRETARY 1.0 0.0 X X 0 0 0 STEVEN J PRINCE TREASURER/PAST CHAIR 2.0 0.0 X X 0 0 0 SHERI ROSENFELD BOARD MEMBER 1.0 0.0 X 0 0 0 MICHAEL WERNER CHAIRMAN 5.0 0.0 X X 0 0 0 ROBERT WERNER CHAIR (END 6/2020) 5.0 0.0 X 0 0 0 BRUCE YABLON BOARD MEMBER 1.0 0.0 X 0 0 0 ANDREW ZELENETZ BOARD MEMBER (BEGIN 7/2019) 1.0 0.0 X 0 0 0 633064 0 90903 4 false true false Marriott Business Services PO Box 402642 ATLANTA GA 30384 VENUE & CATERING 911522 BUILD CONSULTING LLC 1101 14TH STREET SUITE 830 WASHINGTON DC 20005 IT CONSULTING 335388 BLACKBAUD INC 2000 DANIEL DRIVE CHARLESTON SC 29492 CONSULT/SYSTEM MAINT 200606 AOIC LLC 1 East Uwchlan Ave Suite 408 EXTON PA 19341 VENUE & CATERING 100044 4 21568 1684793 8072117 415184 9778478 EDUCATION PROGRAMS & PATIENT SERVICES 900099 3922980 3922980 3922980 312354 312354 0 0 0 0 0 416239 415184 1055 1055 1055 129000 1684793 201271 -72271 -72271 0 0 0 0 0 0 OTHER ACTIVITES 2356 2356 2356 13944952 3922980 243494 1017298 1017298 42600 42600 10000 10000 0 484989 247332 92012 145645 0 2097907 1069063 398108 630736 58584 29769 11127 17688 280675 142391 57999 80285 282338 147035 48554 86749 0 58156 6427 47937 3792 82227 82227 30000 30000 0 0 718806 427945 59027 231834 162540 141638 370 20532 184877 158249 9227 17401 74489 57684 6459 10346 0 393104 200320 74597 118187 323554 271810 7750 43994 0 1145468 1007017 45211 93240 0 0 171075 87177 32464 51434 25730 13111 4883 7736 PROCESSSING FEES AND OTHER 174091 72093 9887 92111 REPAIRS AND MAINTENANCE 45706 23291 8673 13742 LICENSE AND PERMITS 22441 11191 4168 7082 MISCELLANEOUS AND OTHER EXPENS 284738 153992 37623 93123 8171393 5367433 1038303 1765657 1559816 3166522 13125562 17629218 200000 100000 637160 973670 0 0 0 0 0 0 0 0 270859 222328 709901 517755 334307 192146 325967 425759 0 0 0 0 0 0 0 0 16453671 22709643 607815 600502 2997464 2614298 178733 782300 0 0 0 0 0 0 0 0 0 0 0 0 3784012 3997100 X 4602060 4684499 8067599 14028044 12669659 18712543 16453671 22709643 5773559 269325 X false true X true false X 6847149 7784192 7229093 7623538 9778478 39262450 0 0 6847149 7784192 7229093 7623538 9778478 39262450 12793576 26468874 57884 95465 116297 227921 312354 809921 0 5680 18492 15189 14788 2356 56505 40128876 16161363 0.65960 0.70590 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED false true false false false false true 32996 false true 108424 141420 false Schedule C, Part II-B, Line 1 OTHER LOBBYING ACTIVITIES: CONTACT WITH LEGISLATORS, THEIR STAFF, GOVERNMENT OFFICIALS, LEGISLATIVE BODIES, AND ASSOCIATED GRASSROOTS ACTIVITIES TO PRESENT ISSUES OF CONCERN RELATED TO LYMPHOMA. 113640 36465 77175 592725 479167 113558 3536 2123 1413 192146 0 0 X 15419211 269323 1003665 1272988 14146223 -201271 -201271 13944952 9376329 1003665 201271 1204936 8171393 8171393 Schedule D, Part X, Line 2: THE FOUNDATION RECOGNIZES THE EFFECT OF INCOME TAX POSITIONS ONLY IF THOSE POSITIONS ARE MORE LIKELY THAN NOT OF BEING SUSTAINED. INCOME GENERATED FROM ACTIVITIES UNRELATED TO THE FOUNDATION'S EXEMPT PURPOSE IS SUBJECT TO TAX UNDER INTERNAL REVENUE CODE SECTION 511. THE FOUNDATION DID NOT RECOGNIZE ANY UNRELATED BUSINESS INCOME TAX LIABILITY FOR THE YEAR ENDED JUNE 30, 2020 OR 2019. Schedule D, Part XI & XII, lINE 4B & 2D EXPENSES RELATED TO FUNDRAISING EVENTS ARE REPORTED IN PART VIII, STATEMENT OF REVENUE, LINE 8B, TOGETHER WITH FUNDRAISING EVENTS REVENUE. North America 10000 CHECK CASH 1 false false false false false false Team LRF 837294 837294 17552 29684 1575 4386 Annual Gala 799293 677793 121500 904 118155 3750 7956 2 177206 169706 7500 5 13679 3625 1813793 1684793 129000 18461 161518 8950 12342 201271 -72271 true University of Washington 617 East Lake Ave E CE3-300 Seattle WA 98109 916001537 State Entity 225000 CASH Optimizing Checkpoint-Inhibitor Combinations in the Management of Classic Hodgkin Lymphoma University of Texas MD Anderson Cancer Center 1515 Holcombe Blvd Houston TX 77030 746001118 State Entity 225000 CASH Univeristy of North Carolina at Chapel Hill 170 Manning Drive Campus Box 7295 Chapel Hill NC 275997295 566001393 501(C)(3) 225000 CASH Joan and Sanford I Weill Medical College of Cornel 413 East 69th Street Belfer Researc Room 1560 NEW YORK NY 10021 131623978 Corporation 105000 CASH Joan and Sanford I Weill Medical College of Cornel 414 East 69th Street Belfer Researc Room 1428 NEW YORK NY 10021 131623978 Corporation 105000 CASH Northwestern University Feinberg School of Medicin 676 N St Claire Street Suite 850 Chicago IL 60611 362167817 501(C)(3) 105000 CASH The Trusttes of the Univeristy of Pennsylvania 705 Stellar Chance Building Philadelphia PA 231352685 231352685 501(c)(3) 105000 CASH Joan and Sanford I Weill Medical College of Cornel 1300 York Avenue Box 89 New York NY 10065 131623978 Corporation 105000 CASH Joan and Sanford I Weill Medical College of Cornel 1300 York Avenue E907 New York NY 10029 131623978 Corporation 105000 CASH City of Hope and Beckman Research Institute 1500 E DUARTE RD DUARTE CA 91010 953435919 501(c)(3) 105000 CASH Emory University - Winship Cancer Institute 1365 Clifton Road NE Building B 401 Atanta GA 30322 580566256 58-0566256 10000 CASH Weill Cornell Medical College 520 East 70th Street Starr Pavilion NEW YORK NY 10065 131623978 CORPORATION 10000 CASH St Jude Children Research Hospital Inc 262 Danny Thomas Place 260 Memphis TN 381053678 620646012 501(c)(3) 10000 CASH University of UtahHuntsman Cancer Institute 2000 Circle of Hope Research North Salt Lake City UT 84103 876000525 501(c)(3) 10000 CASH University of Texas MD Anderson Cancer Center 1515 Holcombe Blvd Houston TX 77030 746001118 State Entity 10000 CASH University of Iowa 200 Hawkins Dr Iowa City IA 52242 426004813 STATE GOV 10000 CASH 11 5 Patient Aid Grants 426 42600 CASH patient aid grants Schedule I, Part I, Line 2 LRF'S EXPERT SCIENTIFIC ADVISORY BOARD (SAB) CONDUCTS PEER REVIEW FOR ALL GRANT PROPOSALS AND RECOMMENDS THE HIGHEST-SCORING PROPOSALS TO THE LRF BOARD OF DIRECTORS FOR FUNDING. THE BOARD OF DIRECTORS THEN CONSIDERS AND APPROVES THE GRANTS WHICH ARE TO BE FUNDED. ONCE A GRANT IS APPROVED AND ACCEPTED BY THE GRANTEE, THE GRANTEE WILL BEGIN TO RECEIVE INSTALLMENTS BASED UPON THE PAYMENT SCHEDULE AS DICTATED IN THE GRANT CONTRACT. THE SAB AND LRF'S RESEARCH DEPARTMENT ANNUALLY REVIEW EACH GRANTEE'S PROGRESS AGAINST DELIVERABLES AND APPROVES THE CONTINUATION OF GRANT PAYMENTS. Schedule I, Part III LRF PROVIDES FINANCIAL ASSISTANCE TO LYMPHOMA PATIENTS WHO STRUGGLE TO PAY FOR EXPENSES RELATED TO THEIR LYMPHOMA TREATMENTS, SUCH AS MEDICAL BILLS AND TRANSPORTATION COSTS. LRF SUPPORT SERVICES STAFF REVIEWS THE APPLICATIONS, VALIDATES APPLICATION CRITERIA AND SUBMITS APPLICATIONS FOR PAYMENT APPROVAL TO DEPARTMENT LEADERSHIP. X X X false false false false false false false true false MEGHAN GUTIERREZ CHIEF EXECUTIVE OFFICER 263756 25000 11721 0 1018 0 301495 0 0 0 CAROLINA FLORES SENIOR DIRECTOR OF FINANCE 141923 6988 0 41241 0 190152 0 0 0 Schedule J, Part I line 7 MEGHAN GUTIERREZ, CEO, RECEIVED DISCRETIONARY, NON-FIXED BONUS PAYMENT IN CALENDAR YEAR 2019, WHICH IS APPROVED BY THE CHAIR OF THE ORGANIZATION. X 17 415184 Market Price false true false FORM 990, PART I, LINE 1 LRF IS THE NATION'S LARGEST NON-PROFIT ORGANIZATION DEVOTED EXCLUSIVELY TO FUNDING INNOVATIVE RESEARCH AND SERVING THE LYMPHOMA COMMUNITY THROUGH A COMPREHENSIVE SERIES OF EDUCATION PROGRAMS, OUTREACH INITIATIVES, AND PATIENT SERVICES. LRF INVESTS MILLIONS OF DOLLARS EVERY YEAR TO COMBAT LYMPHOMA AND ASSIST THOSE WHOSE LIVES HAVE BEEN AFFECTED BY A LYMPHOMA DIAGNOSIS. LRF IS SUPPORTED BY MORE THAN 10,000 VOLUNTEERS WHO CONTRIBUTE THEIR TIME AND TALENTS TO FURTHER THE LRF MISSION AND SERVE THEIR LOCAL COMMUNITIES. LRF HAS EARNED THE TRUST OF INDIVIDUALS, PRIVATE FOUNDATIONS, PUBLIC COMPANIES, AND ORGANIZATIONS THAT FUND ITS WORK BY DEMONSTRATING A HISTORY OF CAREFUL AND PROVEN FINANCIAL STEWARDSHIP. FORM 990, PART III, LINE 1 - ORGANIZATION'S MISSION LRF IS DEDICATED TO IDENTIFYNG A CURE THROUGH AN INNOVATIVE RESEARCH PROGRAM AND TO HELPING MEMBERS OF THE LYMPHOMA COMMUNITY BY PROVIDING COMPREHENSIVE, DISEASE-SPECIFIC PROGRAMS AND SUPPORT SERVICES. LRF INVESTS MILLIONS OF DOLLARS EVERY YEAR TO COMBAT LYMPHOMA AND ASSIST THOSE WHOSE LIVES HAVE BEEN AFFECTED BY A LYMPHOMA DIAGNOSIS. LRF IS SUPPORTED BY MORE THAN 10,000 VOLUNTEERS WHO CONTRIBUTE THEIR TIME AND TALENTS TO FURTHER THE LRF MISSION AND SERVE THEIR LOCAL COMMUNITIES. LRF HAS EARNED THE TRUST OF INDIVIDUALS, PRIVATE FOUNDATIONS, PUBLIC COMPANIES, AND ORGANIZATIONS THAT FUND ITS WORK. BY DEMONSTRATING A HISTORY OF CAREFUL AND PROVEN FINANCIAL STEWARDSHIP. Form 990, Part III, line 4b RESEARCH: LRFS RESERCH PROGRAM IS GUIDED BY THE LRF SCIENTIFIC ADVISORY BOARD (SAB), COMPRISED OF 45 OF THE WORLD'S LEADING EXPERTS IN LYMPHOMA RESEARCH AND PATIENT CARE. LRF FACILITATES NUMEROUS DISEASE-SPECIFIC GLOBAL CONSORTIA (INCLUDING PROGRAMS FOR FOLLICULAR, MARGINAL ZONE, MANTLE CELL AND ADOLESCENT AND YOUNG ADULT LYMPHOMAS) AND DEVELOPS SCIENTIFIC MEETINGS (INCLUDING WORKSHOPS ADDRESSING NEW LYMPHOMA AND CLL THERAPIES AND CLINICAL TRIALS) ANNUALLY, CONVENING INTERNATIONAL EXPERTS TO SHARE RESEARCH FINDINGS AND COLLABORATE, WITH A GOAL OF ADVANCING THE MOST PROMISING LYMPHOMA AND CLL RESEARCH. LRF FUNDS RELEVANT SENIOR INVESTIGATOR RESEARCH GRANTS AS WELL, SEEKING TO DEVELOP NEW TREATMENTS FOR LYMPHOMA. TO ENSURE THAT THE NEXT GENERATION OF CANCER RESEARCHERS ARE DEDICATED TO STUDYING LYMPHOMA, THE FOUNDATION IS COMMITTED TO INVESTING IN EARLY CAREER SCIENTISTS WHO HAVE THE GREATEST ABILITY TO IMPACT THE FUTURE OF LYMPHOMA RESEARCH. THE FOUNDATION'S EARLY CAREER INVESTIGATOR GRANT PORTFOLIO INCLUDES THE LRF CLINICAL CAREER DEVELOPMENT AWARD, LYMPHOMA SCIENTIFIC RESEARCH MENTORING PROGRAM, AND LRF POSTDOCTORAL FELLOWSHIP. Form 990, Part VI, Section A, Line 2 Michael Werner and Robert Werner have a family relationship. Form 990, Part VI, Section B, Line 11b THE ORGANIZATION'S FORM 990 IS PREPARED INTERNALLY BY THE FINANCE DEPARTMENT AND IS REVIEWED BY MANAGEMENT BEFORE REVIEW BY THE ORGANIZATION'S INDEPENDENT ACCOUNTING FIRM. THE FORM 990 IS THEN REVIEWED BY THE AUDIT COMMITTEE AND THE BOARD FOR COMMENT. Form 990, Part VI, Section B, Line 12c LRF HAS A CONFLICT OF INTEREST POLICY WHICH REQUIRES BOARD MEMBERS, OFFICERS, AND STAFF, TO REVIEW AND SIGN ANNUALLY. DURING THE FY20 FINANCIAL AUDIT, LRF'S EXTERNAL AUDITORS REVIEWED THE BOARD AND OFFICERS' STATEMENTS. NO CONFLICT OF INTERESTS WERE REPORTED FOR THE FISCAL PERIOD ENDING JUNE 30, 2020. IN 2014, LRF ESTABLISHED A FORMAL PROCESS FOR REVIEW AND DISPOSITION OF POTENTIAL CONFLICTS OF INTEREST IN ACCORDANCE WITH THE PROVISIONS OF THE NEW YORK NON-PROFIT REVITALIZATION ACT OF 2013. FORM 990, PART VI, SECTION B, LINE 15 THE ORGANIZATION SETS COMPENSATION IN A MANNER GIVING RISE TO A REBUTTABLE PRESUMPTION THAT THE COMPENSATION IS REASONABLE UNDER STANDARDS SET FORTH IN TREASURY REGULATIONS SECTION 53.4958-6. SALARIES OF THE SENIOR STAFF, INCLUDING THE CEO, ARE DETERMINED BASED UPON MARKET INFORMATION COMPARABLE TO THE POSITION IN OTHER NON-PROFIT ORGANIZATIONS. THE CEO'S COMPENSATION IS APPROVED BY THE EXECUTIVE COMMITTEE (EC), WHICH HAS BEEN DULY AUTHORIZED BY THE BOARD AND CONSISTS OF INDEPENDENT MEMBERS, AND THE APPROVAL IS DOCUMENTED CONTEMPORANEOUSLY IN THE EC MINUTES. Form 990, Part VI, Section C, Line 19 FINANCIAL STATEMENTS ARE ON THE ORGANIZATION'S WEBSITE FOR PUBLIC VIEWING. SIGNED CONFLICT OF INTERESTS FORMS AND GOVERNING DOCUMENTS ARE KEPT ON FILE IN LRF'S MAIN OFFICE AND AVAILABLE FOR VIEW ON-SITE. LRF Research Inc Wall Street Plaza/88 Pine St Ste New York NY 10005 611844536 Investment NY Lymphoma Resear C 0 0 1.00000 true false false false false false false false false false false false false false true true false false false false LRF RESEARCH INC N 57 Invoices paid